Apr 4, 2014

FDA Approves CardioCell’s Phase 2A Trial For CHF Stem Cell Therapy

CardioCell LLC announced that it has received FDA approval for its investigational new drug (IND) application for a U.S.-based Phase IIA clinical study evaluating its allogeneic stem-cell therapy for patients with chronic heart failure (CHF). READ FULL ARTICLE